|
Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Results of the randomized phase II PRODIGE 28-time UNICANCER study. |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Merck Sharp & Dohme; Novartis; SERVIER |
Consulting or Advisory Role - Pierre Fabre; Roche |
Travel, Accommodations, Expenses - Roche; SERVIER |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bayer; Merck; MSD; Pierre Fabre; Roche; Sanofi; SERVIER |
Consulting or Advisory Role - Amgen; Bayer; Merck; MSD; Pierre Fabre; Roche; Sanofi; SERVIER |
Travel, Accommodations, Expenses - Amgen; Bayer; Merck; MSD; Pierre Fabre; Roche; Sanofi; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Advanced Accelerator Applications; Amgen; Ipsen; Novartis; Sanofi; SERVIER; Tillotts Pharma |
|
Travel, Accommodations, Expenses - Amgen; Ipsen; Novartis; Pfizer; Sanofi |
|
|
No Relationships to Disclose |
|
Christelle De La Fouchardiere |
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; Pierre Fabre; Roche; SERVIER; Shire |
|
Travel, Accommodations, Expenses - Amgen; Amgen; Bristol-Myers Squibb; Celgene; Roche; Roche; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Research Funding - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Grunenthal; Merck Serono; MSD Oncology; Roche |
Speakers' Bureau - Amgen; Pierre Fabre; Sanofi; Servier |
Travel, Accommodations, Expenses - Merck Serono; Roche; Servier |